Phathom Pharma CLO Receives 210,000 Stock Options in Executive Compensation Grant

Phathom Pharmaceuticals reported a Form 4 filing on June 28, 2025, disclosing stock option grants to Anne Marie Cook, the company's Chief Legal Officer & Corporate Secretary.

Rhea-AI Filing Summary

Phathom Pharmaceuticals reported a Form 4 filing on June 28, 2025, disclosing stock option grants to Anne Marie Cook, the company's Chief Legal Officer & Corporate Secretary.

Key transaction details:

• Granted 210,000 stock options to purchase common stock
• Exercise price set at $9.47 per share
• Grant date: June 23, 2025
• Expiration date: June 22, 2035

The options follow a 4-year vesting schedule: 25% vests on June 23, 2026, with the remainder vesting in equal monthly installments over the following three years, contingent on continuous service. This grant appears to be part of the company's executive compensation program.

Insider Trade Summary

Grant/Award: 210,000 shares

Grant/Award 1 txn

Insider Cook Anne Marie

Role Chief Legal Off. & Corp. Sec.

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	210,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 210,000 contracts (Direct)

Footnotes (1)

1. F1. The stock option will vest with respect to 25% of the shares of common stock on June 23, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did PHAT's Chief Legal Officer receive on June 23, 2025?

PHAT's Chief Legal Officer Anne Marie Cook received 210,000 stock options (right to buy) on June 23, 2025, with an exercise price of $9.47 per share.

What is the vesting schedule for PHAT CLO's June 2025 stock options?

The stock options vest 25% on June 23, 2026 (first anniversary), with the remaining shares vesting in equal monthly installments over the following three years, subject to continuous service with PHAT.

When do PHAT's stock options granted to Anne Marie Cook expire?

The stock options granted to Anne Marie Cook expire on June 22, 2035, ten years from the grant date.

What is the exercise price of PHAT's stock options granted to their Chief Legal Officer in June 2025?

The exercise price of the stock options granted to PHAT's Chief Legal Officer is $9.47 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2025 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cook Anne Marie

(Last) (First) (Middle)

C/O PHATHOM PHARMACEUTICALS, INC.

100 CAMPUS DRIVE, SUITE 102

(Street)

FLORHAM PARK NJ 07932

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Phathom Pharmaceuticals, Inc. [ PHAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Off. & Corp. Sec.

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.47	06/23/2025		A		210,000		(1)	06/22/2035	Common Stock	210,000	$0	210,000	D

Explanation of Responses:

1. The stock option will vest with respect to 25% of the shares of common stock on June 23, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.

	/s/ Anne Marie Cook	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.